Zielinski R, Lyakhov I, Jacobs A, Chertov O, Kramer-Marek G, Francella N, Stephen A, Fisher R, Blumenthal R, Capala J. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
J Immunother. 2009 Oct;32(8):817-25.
Link to PubMed

Tolmachev V, Orlova A, Pehrson R, Galli J, Baastrup B, Andersson K, Sandström M, Rosik D, Carlsson J, Lundqvist H, Wennborg A, Nilsson FY. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Cancer Res. 2007 Mar 15;67(6):2773-82.
Link to PubMed

A vast number of other publications illustrate the broad applicability of Affibody® molecules, starting with the first publication of the concept in 1997. A list of selected references is presented here.